Phase III trial signals promising treatment option for hyperphosphatemia

Phase III trial signals promising treatment option for hyperphosphatemia

The trail demonstrates that a swallowable, low-pill, non-absorbed iron polymer can match or exceed sevelamer in phosphate control.The post Phase III trial signals promising treatment option for hyperphosphatemia appeared first on Clinical Trials Arena.

AP301 phase 3 trial highlights Alebund’s potential to differentiate in HP space, says GlobalData - GlobalData

Alebund Pharmaceuticals announced positive topline phase III results highlighting that the use of AP301 demonstrated a statistically significant and clinically meaningful improvement in serum phosphorus control in dialysis patients with hyperphosphatemia (HP). If approved, AP301 could potentially address two unmet needs in HP management: poor patient adherence and inadequate phosphorus control, says GlobalData, a leading data and analytics compa…